On This Day in Health: July 13, 2023
On July 13, 2023, the U.S. Food and Drug Administration approved Opill, a norgestrel tablet, for nonprescription use to prevent pregnancy. It was the first daily oral contraceptive cleared for sale in the United States without a prescription. The decision meant consumers could obtain the progestin-only pill at drugstores, convenience stores, grocery stores, and online without first visiting a clinician for a prescription. The manufacturer determined the timing of retail availability and price, so approval did not place the product on shelves immediately. Other oral contraceptive formulations remained prescription medicines.
Norgestrel was not a new active ingredient. Its contraceptive effectiveness had supported prescription approval decades earlier, and the 2023 application asked the FDA to switch its status. For a prescription-to-nonprescription switch, the agency evaluates whether people can select and use the medicine safely and effectively by following the label without professional supervision. Studies submitted for Opill examined whether consumers understood its Drug Facts instructions. The FDA concluded that comprehension and use data supported nonprescription access when the tablet was taken as directed, including taking one pill at the same time every day.
The approval reduced one access barrier but did not remove every limitation. Opill does not protect against HIV or other sexually transmitted infections, and it is not emergency contraception. Missing a dose or taking interacting medicines can reduce effectiveness. The label warns people with current or past breast cancer not to use it and directs consumers with certain questions or symptoms to seek medical advice. Irregular bleeding, headaches, dizziness, nausea, and abdominal symptoms are among the possible effects. Cost, pharmacy stocking, privacy, language access, and understanding the instructions could still influence whether the new option was practical for an individual.
The public-health significance was broader than a change in retail classification. Requiring a prescription can create delays related to appointments, transportation, time off work, insurance, and clinician availability. Allowing direct purchase offered another route to contraception and greater control over reproductive decisions. The FDA also noted the health consequences associated with unintended pregnancy, including delayed prenatal care and increased risk of preterm delivery. July 13 marks a regulatory milestone rather than the invention of the pill: an established medicine crossed into nonprescription use after the agency judged that consumers could use its labeling without a prescriber. Ongoing education and postmarket monitoring remained necessary because wider access also meant more people would make decisions independently without a clinician present.
Opill contains 0.075 milligrams of norgestrel, a progestin-only medicine. The active ingredient had already been used as a prescription contraceptive.
The July 13, 2023 action was the first U.S. approval of a daily oral contraceptive for nonprescription use.
Approval did not guarantee immediate availability or affordability. The manufacturer controlled the launch schedule and price, while retailers decided whether to stock the product.
The pill must be taken every day at the same time and does not prevent sexually transmitted infections or work as emergency contraception.
The decision created a path to oral contraception without an appointment or prescription, potentially reducing delays and logistical barriers.
It also demonstrated the FDA's prescription-to-nonprescription process, which depends on evidence that consumers can understand the label and use the product safely.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.